Table 1.
Patient characteristics
| Patient characteristics (TAS cohort, N = 391) | |
|---|---|
| Age at study inclusion [years], median (range) | 62 (29–89) |
| Weight [kg], median (range) | 66.8 (37–145) |
| Sex, n (%) | |
| Female | 71 (18) |
| Male | 320 (82) |
| Location of primary tumora, n (%) | |
| Oropharynx | 110 (28) |
| Hypopharynx | 94 (24) |
| Larynx | 54 (14) |
| Oral cavity | 97 (25) |
| Other location | 72 (18) |
| Prior therapy, n (%) | |
| Radiotherapy | 320 (82) |
| Surgery | 264 (68) |
| Disease progression at study inclusion, n (%) | |
| Local recurrence only | 198 (51) |
| Distant metastases only | 119 (30) |
| Local recurrence and distant metastases | 74 (19) |
| Charlson Comorbidity Index at study inclusion, n (%) | |
| 0 | 188 (48) |
| 1 | 79 (20) |
| > 1 | 124 (32) |
| ECOG performance status at treatment initiation, n (%) | |
| 0 | 65 (17) |
| 1 | 225 (58) |
| ≥ 2 | 77 (20) |
| Missing | 24 (6) |
| Alcohol consumption, n (%) | |
| Never | 87 (22) |
| Several times per month | 85 (22) |
| Several times per week or daily | 101 (26) |
| Missing | 118 (30) |
| Smoking habits, n (%) | |
| Never smoked | 102 (26) |
| Former smoker | 148 (38) |
| Current smoker | 140 (36) |
| Missing | 1 (0) |
| Pack years, former and current smoker (n = 288), median (range) | 35 (1–200) |
| Applied treatment regimen, n (%) | |
| Radiotherapy + cetuximab | 78 (20) |
| Chemotherapy + cetuximab | 309 (79) |
| Radio-chemotherapy + cetuximab | 4 (1) |
| Applied chemotherapy regimen (n = 313), n (%) | |
| Cisplatin-based | 174 (56) |
| Carboplatin-based | 139 (44) |
TAS Target Analysis Set, ECOG Eastern Cooperative Oncology Group. aMultiple locations per patient possible